The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma

Huen, Auris; Kim, Ellen J.

doi:10.1016/j.det.2015.05.007

Cited by 46 publications

(56 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Isotretinoin at doses of 1–3 mg/kg/day achieved ORR of 43–100% and CR <20% with short duration of response (3–15 months) in early MF . Etretinate , no longer available, was studied in the treatment of MF with similar efficacy rates noted.…”

Section: Systemic Therapiesmentioning

confidence: 96%

“…Retinoids exert their effects via RAR and RXT receptor families. In CTCL, retinoids induce cellular differentiation, proliferation and apoptosis and DNA fragmentation of T lymphocytes …”

Section: Skin‐directed Therapiesmentioning

confidence: 99%

“…As a 0.1% gel, it was used in patch stage MF with ORR of 58% and CRR of 35% . All trans retinoic acid has also demonstrated some activity with ORR of 31% in a small study of 13 patients with early MF . Alitretinoin , another retinoid available in gel formulation, has had isolated case reports of success in the treatment of MF both in monotherapy and in combination with other agents.…”

Section: Skin‐directed Therapiesmentioning

confidence: 99%

“…All retinoids are teratogens and thus contraindicated in pregnancy and require special precautions in women of childbearing potential . Skin irritation is the main potential side effect but can be managed with reducing frequency of application and emollient use.…”

Section: Skin‐directed Therapiesmentioning

confidence: 99%

See 3 more Smart Citations

Management of cutaneous T‐cell lymphomas: Established and emergent therapies

et al. 2019

View full text Add to dashboard Cite

Cutaneous T-cell lymphoma is an uncommon group of non-Hodgkin's lymphoma primarily affecting the skin. It is comprised of a variety of entities with different clinical behaviours and prognosis. Mycosis fungoides is the commonest subtype, and S ezary syndrome is a much rarer form of cutaneous T-cell lymphoma. At this stage, control rather than cure is the goal of therapy, with particular emphasis placed on preserving quality of life. Our review of the efficacy, safety profile and accessibility of treatment modalities for mycosis fungoides/S ezary syndrome is a tailored guide for the clinician treating these rare conditions.

show abstract

Section: Systemic Therapiesmentioning

confidence: 96%

“…Retinoids exert their effects via RAR and RXT receptor families. In CTCL, retinoids induce cellular differentiation, proliferation and apoptosis and DNA fragmentation of T lymphocytes …”

Section: Skin‐directed Therapiesmentioning

confidence: 99%

Section: Skin‐directed Therapiesmentioning

confidence: 99%

Section: Skin‐directed Therapiesmentioning

confidence: 99%

See 2 more Smart Citations

Management of cutaneous T‐cell lymphomas: Established and emergent therapies

et al. 2019

View full text Add to dashboard Cite

show abstract

“…SDT, including topical steroids, PUVA, UVB, radiation and topical chemotherapies are used for localized disease control while systemic therapies are reserved for both limited‐stage disease that is poorly controlled with SDT alone and advanced‐stage disease. Systemic treatment options that have been utilized in MF/SS include retinoids , interferon alpha , single agent or combination chemotherapy , HDAC inhibitors , and antibody‐based therapies . For SS, extracorporeal photophoresis (ECP) is frequently used in the front‐line setting .…”

Section: Introductionmentioning

confidence: 99%

A retrospective comparative outcome analysis following systemic therapy in Mycosis fungoides and Sezary syndrome

et al. 2016

View full text Add to dashboard Cite

Cutaneous T-cell lymphomas (CTCL), with few exceptions, remain incurable and treatment is largely palliative. We performed a retrospective analysis of systemic treatment outcomes of patients diagnosed with MF/SS. We identified 223 patients with MF/SS evaluated at a single institution from 1997 to 2013. Disease stage at diagnosis, time of treatment, and treatments received were retrospectively analyzed using our CTCL database. The primary endpoint was time to next treatment (TTNT). Treatment outcomes were analyzed using Kaplan-Meier method and comparisons among groups were made using log-rank analysis. A superior TTNT was associated with retinoid or interferon therapies when compared with HDAC inhibitors or systemic chemotherapy. Retinoids and interferon were associated with superior TTNT in both limited-stage and advanced stage disease. Extracorporeal photophoresis (ECP) had a superior TTNT in Sezary Syndrome. HDAC inhibitors and chemotherapy were associated with inferior TTNT in both limited stage disease and advanced stage disease. With the exception of interferon, retinoids, or ECP, durable responses are rarely achieved with systemic therapies in MF/SS patients, particularly those with advanced-stage disease. Therefore, clinical trial participation with novel agents should be encouraged. Am. J. Hematol. 91:E491-E495, 2016. © 2016 Wiley Periodicals, Inc.

show abstract

Alitretinoin in the treatment of cutaneous T‐cell lymphoma

Kaemmerer¹,

Stadler²,

Frommherz³

et al. 2021

Cancer Medicine

View full text Add to dashboard Cite

Introduction In this survey, we analyzed data from patients suffering from the most common cutaneous T‐cell lymphomas (CTCLs) subtypes mycosis fungoides (MF) and Sézary syndrome (SS), treated with the retinoid alitretinoin during a 7‐year period at our outpatient department between 2015 and 2020. Materials and Methods We analyzed patient medical records including TNMB stage, side effects under therapy with alitretinoin, time to next treatment (TTNT), and previous photo documentation. Results A total of 35 patients with MF (n = 28) and SS (n = 7) were included in the study, of whom 69% were male and 31% were female. The mean age of onset was 56 ± 15 years in MF and 65.4 ± 10.8 years in SS with 51.4% having early stage (IA–IIA) and 48.6% having advanced stage (IIB–IVA) CTCL. Of these patients 37.2% responded to alitretinoin, 28.6% had a stable course, and 34.3% experienced progression. Alitretinoin was administered as a monotherapy (25.7%) or combined with five concomitant therapies (74.2%), most frequently with ECP (31.4%) and PUVA (11.4%). 63% did not report any side effects, most often hypertriglyceridemia (20%) was described. Conclusion Considering that nearly two thirds of the CTCL patients treated with alitretinoin showed a response or stable disease, together with a low number of side effects and low cost compared to bexarotene, alitretinoin may be a potential alternative in the treatment of less advanced CTCLs. This survey represents the largest number of recorded therapies with the retinoid alitretinoin in CTCLs in a European patient collective.

show abstract

The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma

Cited by 46 publications

References 69 publications

Management of cutaneous T‐cell lymphomas: Established and emergent therapies

Management of cutaneous T‐cell lymphomas: Established and emergent therapies

A retrospective comparative outcome analysis following systemic therapy in Mycosis fungoides and Sezary syndrome

Alitretinoin in the treatment of cutaneous T‐cell lymphoma

Contact Info

Product

Resources

About